Antibiotics in Inflammatory Bowel Diseases: Do We Know What We're Doing?

Overview

Journal Transl Pediatr

Publisher AME Publishing Company

Specialty Pediatrics

Date 2019 Mar 19

PMID 30881898

Citations 19

Authors

Oren Ledder

Affiliations

Soon will be listed here.

Abstract

Despite the revolution in inflammatory bowel disease (IBD) treatment over the past two decades with the advent of biological therapies, there remains a substantial proportion of patients with inadequate or unsustained response to existent therapies. The overwhelming focus of IBD therapeutics has been targeting mucosal immunity, however with the developing evidence base pointing to the role of gut microbes in the inflammatory process, renewed focus should be placed on the impact of manipulating the microbiome in IBD management. This review provides an overview of the evidence implicating bacteria in the pathogenesis of gut inflammation in IBD and provides an overview of the evidence of antibiotics in IBD treatment. We also suggest a potential role of antibiotics in clinical practice based on available evidence and clinical experience.

Citing Articles

Fetal and Early-Life Antibiotics and Risk of Pediatric Inflammatory Bowel Disease: A Population-Based Nationwide Register Study.

Andersen S, Hestetun S, Bernklev T, Perminow G, Stordal K J Pediatr Clin Pract. 2025; 12:200096.

PMID: 39949419 PMC: 11824603. DOI: 10.1016/j.jpedcp.2024.200096.

"Pleiotropic" Effects of Antibiotics: New Modulators in Human Diseases.

Airola C, Severino A, Spinelli I, Gasbarrini A, Cammarota G, Ianiro G Antibiotics (Basel). 2025; 13(12.

PMID: 39766566 PMC: 11727521. DOI: 10.3390/antibiotics13121176.

Prevalence of Plasmid-Mediated Quinolone Resistance Genes in Isolates From Colonic Biopsies of Iranian Patients With Inflammatory Bowel Diseases: A Cross-Sectional Study.

Alipour S, Owrang M, Rajabnia M, Olfatifar M, Kazemian H, Houri H Health Sci Rep. 2024; 7(12):e70204.

PMID: 39698518 PMC: 11652390. DOI: 10.1002/hsr2.70204.

Revolutionizing Gastrointestinal Disorder Management: Cutting-Edge Advances and Future Prospects.

Suri C, Pande B, Sahu T, Suhasini Sahithi L, Verma H J Clin Med. 2024; 13(13).

PMID: 38999541 PMC: 11242723. DOI: 10.3390/jcm13133977.

The impact of antibiotic exposure on antibiotic resistance gene dynamics in the gut microbiota of inflammatory bowel disease patients.

Zhang Y, Xue G, Wang F, Zhang J, Xu L, Yu C Front Microbiol. 2024; 15:1382332.

PMID: 38694799 PMC: 11061493. DOI: 10.3389/fmicb.2024.1382332.

References

Rafii F, van Lieshout L . Changes in bacterial enzymes and PCR profiles of fecal bacteria from a patient with ulcerative colitis before and after antimicrobial treatments. Dig Dis Sci. 1999; 44(3):637-42. DOI: 10.1023/a:1026634229934. View

Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M . Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci. 1999; 44(6):1220-1. DOI: 10.1023/a:1026648812439. View

Leiper K, Morris A, Rhodes J . Open label trial of oral clarithromycin in active Crohn's disease. Aliment Pharmacol Ther. 2000; 14(6):801-6. DOI: 10.1046/j.1365-2036.2000.00753.x. View

Mantzaris G, Petraki K, Archavlis E, Amberiadis P, Kourtessas D, Christidou A . A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol. 2001; 36(9):971-4. DOI: 10.1080/003655201750305503. View

Goodgame R, KIMBALL K, Akram S, Ike E, Ou C, SUTTON F . Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. Aliment Pharmacol Ther. 2001; 15(12):1861-6. DOI: 10.1046/j.1365-2036.2001.01099.x. View

Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M . Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002; 122(1):44-54. DOI: 10.1053/gast.2002.30294. View

Arnold G, Beaves M, Pryjdun V, Mook W . Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis. 2002; 8(1):10-5. DOI: 10.1097/00054725-200201000-00002. View

Shafran I, Kugler L, El-Zaatari F, Naser S, Sandoval J . Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Dig Liver Dis. 2002; 34(1):22-8. DOI: 10.1016/s1590-8658(02)80055-x. View

Neut C, Bulois P, Desreumaux P, Membre J, Lederman E, Gambiez L . Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol. 2002; 97(4):939-46. DOI: 10.1111/j.1572-0241.2002.05613.x. View

10.

Labro M . Antibiotics as anti-inflammatory agents. Curr Opin Investig Drugs. 2002; 3(1):61-8. View

11.

Steinhart A, Feagan B, Wong C, Vandervoort M, Mikolainis S, Croitoru K . Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology. 2002; 123(1):33-40. DOI: 10.1053/gast.2002.34225. View

12.

Farrell R, Lamont J . Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am. 2002; 31(1):41-62. DOI: 10.1016/s0889-8553(01)00004-8. View

13.

Ohkusa T, Sato N, Ogihara T, Morita K, Ogawa M, Okayasu I . Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol. 2002; 17(8):849-53. DOI: 10.1046/j.1440-1746.2002.02834.x. View

14.

Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N . Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut. 2002; 52(1):79-83. PMC: 1773498. DOI: 10.1136/gut.52.1.79. View

15.

Rutgeerts P, Geboes K, VANTRAPPEN G, Van Isveldt J, Peeters M, Penninckx F . Rifabutin and ethambutol do not help recurrent Crohn's disease in the neoterminal ileum. J Clin Gastroenterol. 1992; 15(1):24-8. DOI: 10.1097/00004836-199207000-00007. View

16.

Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W . Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther. 2003; 18(11-12):1113-20. DOI: 10.1046/j.1365-2036.2003.01793.x. View

17.

Marco R, Mangano K, Quattrocchi C, Musumeci R, Speciale A, Papaccio G . Curative effects of sodium fusidate on the development of dinitrobenzenesulfonic acid-induced colitis in rats. Clin Immunol. 2003; 109(3):266-71. DOI: 10.1016/s1521-6616(03)00213-4. View

18.

Card T, Logan R, Rodrigues L, Wheeler J . Antibiotic use and the development of Crohn's disease. Gut. 2004; 53(2):246-50. PMC: 1774910. DOI: 10.1136/gut.2003.025239. View

19.

Ott S, Musfeldt M, Wenderoth D, Hampe J, Brant O, Folsch U . Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004; 53(5):685-93. PMC: 1774050. DOI: 10.1136/gut.2003.025403. View

20.

Sartor R . Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004; 126(6):1620-33. DOI: 10.1053/j.gastro.2004.03.024. View